SCHEMBL2095499

SCHEMBL2095499

CCOCCc1ccc2csccc1-2

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
MAPT P10636 1/20 0.42
ALOX15 P16050 1/20 0.42
KMT2A Q03164 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MYC P01106 4/20 0.33
CHEK2 O96017 1/20 0.32
CYP2A6 P11509 1/20 0.31
PDE3A Q14432 1/20 0.31
SLC6A9 P48067 1/20 0.30
HRH2 P25021 1/20 0.30
HRH1 P35367 1/20 0.30
LPL P06858 1/20 0.30
LIPG Q9Y5X9 1/20 0.30
CDC7 O00311 1/20 0.30
DBF4 Q9UBU7 1/20 0.30
GAK O14976 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27329701 0.77 MEN1 (0.38) MEN1USP2MAPTALOX15KMT2A
SCHEMBL2091183 0.74 MEN1 (0.34) MEN1USP2MAPTALOX15KMT2A
SCHEMBL6057086 0.72 DRD2 (0.50) MEN1MAPTKMT2AHSD17B10
SCHEMBL9111503 0.70 MEN1 (0.32) MEN1USP2MAPTALOX15KMT2A
SCHEMBL28141334 0.70 USP2 (0.39) MEN1USP2MAPTALOX15KMT2A
SCHEMBL6598549 0.70 MEN1 (0.39) MEN1USP2MAPTALOX15KMT2A
SCHEMBL28104229 0.70 MEN1 (0.36) MEN1USP2MAPTALOX15KMT2A
SCHEMBL8051996 0.70 MEN1 (0.36) MEN1USP2MAPTALOX15KMT2A
SCHEMBL9548757 0.69 DRD2 (0.47) MEN1MAPTKMT2AHSD17B10
SCHEMBL22548895 0.68 CYP2A6 (0.44) MEN1USP2MAPTALOX15KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 MEN1 4525/4885USP2 1756/4885MAPT 4299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.